Some good news for Friday - industry researcher VentureOne has released data showing that the median valuation for a start-up life science company went up in 2004 from $10MM to $13MM (that value being the value of a company prior to receiving venture capital).
Venture One's explanation for this was more capital being available as well as a fairly finite number of "promising investment opportunities." That's to be expected, though - as the investors get savvier about the industry and what really has a shot, they are going to narrow the field of potential ideas.
Comments